The effect of thalidomide on lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α production was studied by using RAW 264.7 murine macrophage-like cells. Thalidomide significantly inhibited LPS-induced TNF-α production. Thalidomide prevented the activation of nuclear factor (NF)-KB by down-regulating phosphorylation of inhibitory KB factor (IKB), and IKB kinase (IKK)-α and IKK-β Moreover, thalidomide inhibited LPS-induced phosphorylation of AKT, p38 and stress-activated protein kinase (SAPK)/JNK. The expression of myeloid differentiation factor 88 (MyD88) protein and mRNA was markedly reduced in thalidomide-treated RAW 264.7 cells but there was no significant alteration in the expression of interleukin-1 receptor-associated kinase (IRAK) 1 and TNF receptor-associated factor (TRAF) 6 in the cells. Thalidomide did not affect the cell surface expression of Toll-like receptor (TLR) 4 and CD14, suggesting the impairment of intracellular LPS signalling in thalidomide-treated RAW 264.7 cells. Thalidomide significantly inhibited the TNF-α production in response to palmitoyl-Cys(RS)-2,3-di(palmitoyloxy) propyl)-Ala-Gly-OH (Pam3Cys) as a MyD88-dependent TLR2 ligand. Therefore, it is suggested that thalidomide might impair LPS signalling via down-regulation of MyD88 protein and mRNA and inhibit LPS-induced TNF-α production. The putative mechanism of thalidomide-induced MyD88 down-regulation is discussed.
Hideshima T. , Chauhan D., Schlossman R. et al. The role of tumor necrosis factor-α in the pathophysiology of human multiple myeloma: therapeutic applications . Oncogene2001; 20: 4519-4527.
2.
Eisen T., Boshoff C., Mak I. et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer2000; 82: 812-817.
3.
Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs that are potent inhibitors of TNF-alpha . J Immunol1999; 163: 380-386.
4.
Haslett PA, Corral LG, Albert M. et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med1998; 187: 1885-1892.
5.
Zwingenberger K., Wnendt S.Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J Inflamm1995; 46: 177-211.
6.
Sampaio EP, Sarno EN, Galilly R. et al. Thalidomide selectively inhibits tumor necrosis factor-alpha production by stimulated human monocytes. J Exp Med1991; 173: 699-703.
7.
Moreira AL, Sampaio EP, Zmuidzinas A. et al. Thalidomide exerts its inhibitory action on tumor necrosis factor-alpha by enhancing mRNA degradation. J Exp Med1993 ; 177: 1675-1680.
8.
Paul SC, Lv P., Xiao YJ et al. Thalidomide in rat liver cirrhosis: blockade of tumor necrosis factor-alpha via inhibition of degradation of an inhibitor of nuclear factor-kappaB . Pathobiology2006; 73: 82-92.
9.
Ishikawa M., Kanno S., Takayanagi M. et al. Thalidomide promotes the release of tumor necrosis factor-alpha (TNF-alpha) and lethality by lipopolysaccharide in mice. Biol Pharm Bull1998; 21: 638-640.
10.
Kawai T., Adachi O., Ogawa T. et al. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity1999; 11: 115-122.
11.
Shakhov AN, Collart MA, Vassalli P. et al. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med1990; 171: 35-47.
12.
Saklatvala J., Davis W., Guesdon F.Interleukin 1 (IL1) and tumour necrosis factor (TNF) signal transduction. Philos Trans R Soc Lond B Biol Sci1996; 351: 151-157.
13.
Han J., Lee JD, Bibbs L. et al. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science1994; 265: 808-811.
14.
Hambleton J. , Weinstein SL, Lem L. et al. Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. Proc Natl Acad Sci USA1996; 93: 2774-2778.
15.
Herrera-Velit P., Reiner NEBacterial lipopolysaccharide induces the association and coordinate activation of p53/56lyn and phosphatidylinositol 3-kinase in human monocytes. J Immunol1996; 156: 1157-1165.
16.
Chakravortty D., Kato Y., Sugiyama T. et al. The inhibitory action of sodium arsenite on lipopolysaccharide-induced nitric oxide production in RAW 267.4 macrophage cells: a role of Raf-1 in lipopolysaccharide signaling. J Immunol2001; 166: 2011-2017.
17.
Naiki Y., Michelsen KS, Zhanq W. et al. Transforming growth factor-β differentially inhibits MyD88-dependent, but not TRAM-and TRIF-dependent, lipopolysaccharide-induced TLR4 signaling . J Biol Chem2005; 280: 5491-5495.
18.
Keifer JA, Guttridqe DC, Ashburner BP et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem2001 ; 276: 22382-22387.
19.
Zandi E., Rothwarf DM, Delhase M. et al. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for NF-kappaB activation. Cell1997; 91: 243-252.
Ozes ON, Mayo LD, Gustin JA et al. NF-KB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature1999; 401: 82-85.
22.
Ozes ON, Mayo LD, Gustin JA et al. Reply: kinase regulation in inflammatory response. Nature2000; 406: 368-368.
23.
Yamamoto M. , Sato S., Hemmi H. et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature2002; 420: 324-329.
24.
Akira S., Takeda K.Toll-like receptor in innate immunity. Int Immunol2005; 1: 1-14.
25.
Glickman MH , Ciechanover A.The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev2002; 82: 373-428.
26.
Ben-Neriah Y.Regulatory functions of ubiquitination in the immune system. Nat Immunol2002; 3: 20-26.
27.
Lv P., Luo HS, Zhou XP et al. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Arch Med Res2007; 38: 15-27.
28.
Chauhan D., Hideshima T., Mitsiades C. et al. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther2005; 4: 686-692.
29.
Roodman GDBone building with bortezomib. J Clin Invest2008; 118: 462-464.
30.
von Metzler I., Krebbel H., Hecht M. et al. Bortezomib inhibits human osteoclastogenesis . Leukemia2007; 21: 2025-2034.
31.
Kopp EB, Medzitov R.The Toll-receptor family and control of innate immunity. Curr Opin Immunol1999; 11: 13-18.
32.
Dziarski R., Gupta D.Role of MD-2 in TLR2- and TLR4-mediated recognition of Gram-negative and Gram-positive bacteria and activation of chemokine genes. J Endotoxin Res2000; 6: 401-405.
